biotech · Lymphoma, Non-Hodgkin · Systemic Lupus Erythematosus · CRBU
Caribou Biosciences
Caribou Biosciences patent portfolio — 19 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Berkeley, USA
- Founded
- 2012
- Employees
- 131
- Programs
- 4
- Drugs
- 2
- Patents
- 19
Caribou Biosciences patents
19 pharmaceutical patents indexed for Caribou Biosciences. 0 expire within 24 months.
Caribou Biosciences has 19 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11939604
Modified cascade ribonucleoproteins and uses thereof
granted -
US 11932703
Anti-ROR1 antibody and ROR1-targeting engineered cells
granted -
US 11472884
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 11312953
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 11299549
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 11142583
BCMA-CAR-natural killer (NK) cells and methods related thereto
granted -
US 11021542
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 10954498
Modified cascade ribonucleoproteins and uses thereof
granted -
US 10927182
Humanized BCMA antibody and BCMA-CAR-T cells
granted -
US 10711257
Modified cascade ribonucleoproteins and uses thereof
granted -
US 10435678
Modified cascade ribonucleoproteins and uses thereof
granted -
US 10125361
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 9909122
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 9885026
Modified cascade ribonucleoproteins and uses thereof
granted -
US 9809814
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 9803194
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 9725714
Compositions and methods of nucleic acid-targeting nucleic acids
granted -
US 9410198
Compostions and methods of nucleic acid-targeting nucleic acids
granted -
US 9260752
Compositions and methods of nucleic acid-targeting nucleic acids
granted
Frequently asked questions
How many patents does Caribou Biosciences have?
19 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Caribou Biosciences patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.